{"result": "(\"entity\"<|>FRAMINGHAM<|>GEO<|>Framingham is a location known for its cardiovascular risk assessment tables used in medical guidelines.)\n##\n(\"entity\"<|>EUROPEAN GUIDELINES<|>ORGANIZATION<|>The European guidelines provide recommendations for managing dyslipidemias and preventing cardiovascular diseases.)\n##\n(\"entity\"<|>HYPERTRIGLYCERIDEMIA<|>EVENT<|>Hypertriglyceridemia is a medical condition characterized by elevated levels of triglycerides in the blood, which can lead to cardiovascular issues.)\n##\n(\"entity\"<|>LIPOPROTEIN LIPASE<|>PERSON<|>Lipoprotein lipase is an enzyme that plays a crucial role in the metabolism of lipoproteins and triglycerides.)\n##\n(\"entity\"<|>APO C-II<|>PERSON<|>Apolipoprotein C-II is a protein that is essential for the function of lipoprotein lipase and is involved in lipid metabolism.)\n##\n(\"entity\"<|>CARDONA F<|>PERSON<|>Cardona F is an author referenced in the manual of Endocrinology and Nutrition, contributing to the understanding of dyslipidemias.)\n##\n(\"entity\"<|>ALCAIDE J<|>PERSON<|>Alcaide J is an author referenced in the manual of Endocrinology and Nutrition, contributing to the understanding of dyslipidemias.)\n##\n(\"entity\"<|>FERNÁNDEZ GARCÍA JC<|>PERSON<|>Fernández García JC is an author referenced in the manual of Endocrinology and Nutrition, contributing to the understanding of dyslipidemias.)\n##\n(\"entity\"<|>MATA P<|>PERSON<|>Mata P is an author referenced in the document on combined familial hyperlipidemia, contributing to the understanding of lipid disorders.)\n##\n(\"entity\"<|>ALONSO R<|>PERSON<|>Alonso R is an author referenced in the document on combined familial hyperlipidemia, contributing to the understanding of lipid disorders.)\n##\n(\"entity\"<|>RUIZ-GARCIA A<|>PERSON<|>Ruíz-Garcia A is an author referenced in the document on combined familial hyperlipidemia, contributing to the understanding of lipid disorders.)\n##\n(\"entity\"<|>DÍAZ-DÍAZ JL<|>PERSON<|>Díaz-Díaz JL is an author referenced in the document on combined familial hyperlipidemia, contributing to the understanding of lipid disorders.)\n##\n(\"entity\"<|>GONZÁLEZ N<|>PERSON<|>González N is an author referenced in the document on combined familial hyperlipidemia, contributing to the understanding of lipid disorders.)\n##\n(\"entity\"<|>GIJÓN-CONDE T<|>PERSON<|>Gijón-Conde T is an author referenced in the document on combined familial hyperlipidemia, contributing to the understanding of lipid disorders.)\n##\n(\"relationship\"<|>EUROPEAN GUIDELINES<|>FRAMINGHAM<|>The European guidelines utilize the Framingham tables for cardiovascular risk assessment<|>7)\n##\n(\"relationship\"<|>HYPERTRIGLYCERIDEMIA<|>LIPOPROTEIN LIPASE<|>Lipoprotein lipase is involved in the metabolism of triglycerides, which are elevated in hypertriglyceridemia<|>8)\n##\n(\"relationship\"<|>HYPERTRIGLYCERIDEMIA<|>APO C-II<|>Apolipoprotein C-II is essential for the function of lipoprotein lipase, which is crucial in managing hypertriglyceridemia<|>8)\n##\n(\"relationship\"<|>CARDONA F<|>EUROPEAN GUIDELINES<|>Cardona F contributed to the European guidelines on dyslipidemias<|>6)\n##\n(\"relationship\"<|>ALCAIDE J<|>EUROPEAN GUIDELINES<|>Alcaide J contributed to the European guidelines on dyslipidemias<|>6)\n##\n(\"relationship\"<|>FERNÁNDEZ GARCÍA JC<|>EUROPEAN GUIDELINES<|>Fernández García JC contributed to the European guidelines on dyslipidemias<|>6)\n##\n(\"relationship\"<|>MATA P<|>EUROPEAN GUIDELINES<|>Mata P contributed to the document on combined familial hyperlipidemia<|>6)\n##\n(\"relationship\"<|>ALONSO R<|>EUROPEAN GUIDELINES<|>Alonso R contributed to the document on combined familial hyperlipidemia<|>6)\n##\n(\"relationship\"<|>RUIZ-GARCIA A<|>EUROPEAN GUIDELINES<|>Ruíz-Garcia A contributed to the document on combined familial hyperlipidemia<|>6)\n##\n(\"relationship\"<|>DÍAZ-DÍAZ JL<|>EUROPEAN GUIDELINES<|>Díaz-Díaz JL contributed to the document on combined familial hyperlipidemia<|>6)\n##\n(\"relationship\"<|>GONZÁLEZ N<|>EUROPEAN GUIDELINES<|>González N contributed to the document on combined familial hyperlipidemia<|>6)\n##\n(\"relationship\"<|>GIJÓN-CONDE T<|>EUROPEAN GUIDELINES<|>Gijón-Conde T contributed to the document on combined familial hyperlipidemia<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: antomas.                                                  y turbio, y/o anillo sobrenadante, cuando los niveles son mayores. No aparecen xantomas\n              Debido a su carácter genético y a su elevada aterogenicidad, la estratificación del riesgo                                                  si los niveles de triglicéridos están por debajo de 1.000 mg/dl; cuando estos aumentan\n              cardiovascular mediante las tablas de Framingham o el SCORE puede estar infraestimado                                                       pueden aparecer. La hipertrigliceridemia abarca procesos primarios como:\n              en estos pacientes. Las guías europeas para el manejo de las dislipidemias y de preven-                                                     Hipertrigliceridemia familiar. Parece ser transmitida como un trastorno autosómico domi-\n              ción de la enfermedad cardiovascular (ECV) clasifican a los pacientes con hiperlipidemias                                                   nante, pero no se ha identificado la mutación o mutaciones responsables. Se caracteriza\n              familiares de riesgo cardiovascular (RCV) alto, por lo que el objetivo de control lipídico es                                               tanto por una disminución del catabolismo de las VLDL como por un aumento de su pro-\n              un colesterol LDL < 100 mg/dl [clase o fuerza de la recomendación (CdR) I, nivel de calidad                                                 ducción. Los elevados niveles de triglicéridos plasmáticos en ayunas (200-750 mg/dl; 2,3-\n              de la evidencia (NdE) A, y categorización GRADE fuerte)]. El RCV es muy alto cuando los                                                     8,0 mmol/l) suelen ser triglicéridos en VLDL.\n              pacientes con hipercolesterolemia familiar combinada (HFC) tienen además ECV documen-                                                       Déficit familiar de lipoproteína lipasa (LPL) y déficit de apo C-II. El déficit familiar de LPL es un\n              tada, enfermedad renal crónica moderada o grave, diabetes o lesión de órgano diana (CdR I,                                                  trastorno autosómico recesivo, debido a una alteración o ausencia de la LPL, que da lugar a\n              NdE A, GRADE fuerte). En estas situaciones, el objetivo de control lipídico es un colesterol                                                una acumulación de quilomicrones en el plasma. Entre las manifestaciones se encuentran\n              LDL < 70 mg/dl, o una reducción mayor del 50% de los niveles iniciales, cuando no se pueda                                                  xantomas, hepatomegalia, esplenomegalia e infiltración de células espumosas en la médu-\n              alcanzar este objetivo.                                                                                                                     la ósea. El 5-10% de los sujetos con hipertrigliceridemia son heterocigotos para mutaciones\n              En situaciones de hipertrigliceridemia > 400 mg/dl, la determinación del colesterol LDL me-                                                 en este gen y la actividad de la LPL puede estar disminuida en un 20-50%. El déficit familiar\n              diante la fórmula de Friedewald no es precisa, por lo que se usa como objetivo subrogado                                                    de apo C-II es un trastorno autosómico recesivo que causa un déficit funcional de la LPL,\n              (CdR II, NdE B, GRADE fuerte) el colesterol no-HDL.                                                                                         con unas manifestaciones parecidas a la deficiencia de esta enzima. Este trastorno altera\n                                                                                                                                                          la hidrólisis de quilomicrones y VLDL, por lo que se acumulan estas lipoproteínas. Los su-\n              Referencias:                                                                                                                                jetos heterocigotos poseen niveles que se corresponden con la mitad que en los sujetos\n              • Cardona F, Alcaide J, Fernández García JC. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española\n                de Endocrinología y Nutrición; 2015. Capítulo 124. Epidemiología, diagnóstico y clasificación de las dislipemias;                         sanos, y pueden sufrir ligeras elevaciones de los triglicéridos.\n                [citado 11 de noviembre de 2019]. Disponible en: https://manual.seen.es/article?id=55115050-34cc-451f-99b6-4b97ac18103c\n              • Mata P, Alonso R, Ruíz-Garcia A, Díaz-Díaz JL, González N, Gijón-Conde T, et al. Hiperlipidemia familiar combinada: documento de consen-  Déficit de lipasa hepática.        La ausencia de lipasa hepática es un trastorno autosómico re-\n                so. Medicina de Familia. SEMERGEN. 2014;40(7):374-380.                                                                                    cesivo raro que altera el catabolismo de las VLDL e IDL. Además, los individuos con este\n                                                                                                                                                          trastorno presentan HDL-2 elevada, ya que la lipasa hepática interviene en la conversión de\n     8.4 Casos clínicos. Caso clínico 1                                                                                                                   HD\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}